The average age at BC onset was similar in carriers of both the g and c RAD51-135 genotypes (45.0 and 45.9 years; Table 2); however, using Kaplan–Meier survival analysis, the median time to BC development was 45 years (95% CI 36–54) in BCRA2-RAD51-135c carriers and 52 years (95% CI 48–56) in the BRCA2-RAD51-wt group (Plog rank=0.0271, Pbreaslow=0.05). Here, RAD51 is linked to breast cancer.